Centrum

Marksans Pharma: Downgrade it to ‘hold’ with a TP of Rs 31, says Centrum

Marksans Pharma: We downgrade Marksans Pharma (MPL) to Hold from Buy rating with a TP of `31 (earlier `55) based on 18x March’20E EPS of `1.7. MPL’s Q4FY18 results were lower than our expectations.

Markets News

Downgrade Marksans Pharma to ‘hold’ with TP of Rs 31

We downgrade Marksans Pharma (MPL) to Hold from Buy rating with a TP of Rs 31 (earlier Rs 55) based on 18x March’20E EPS of R1.7. MPL’s Q4FY18 results were lower than our expectations.

Markets News

Maintain ‘buy’ on Swaraj Engines with TP of Rs 2,402

Despite a strong growth in the India tractor industry, Swaraj Engines (SWE) reported a moderate volume growth. Considering stellar growth reported by M&M’s tractor division, this performance was below our estimates.

Despite a strong growth in the India tractor industry, Swaraj Engines (SWE) reported a moderate volume growth. News

Invest in equities in tranches in FY 2018-19

The most frequent question these days is whether we are in a bull market or in a bear market. It is natural to hear this question after the spectacular market fall towards the end of financial year 2017-18, bringing back unpl

equity, equities, markets, finance, fiscal deficit News

‘Accumulate’ on Ahluwalia Contracts, TP at Rs 421

Ahluwalia Contracts (India) (ACIL), for Q3FY18, reported decent numbers. Revenue grew 1% y-o-y to Rs 361 crore, growth was muted on the back of GST impact (adjusting for the same, revenue would have been up by 9-10%).

ahluwalia contracts, ACIL, revenue, markets News

Centrum puts ‘hold’ rating on Bharat Financial with TP at Rs 1,193

After several quarters of slower growth in disbursements and loans, the same grew at a robust pace of 58.1% to Rs 4,712 crore and 34.4% to Rs 11,466 crore, respectively as on December 31, 2017.

centrum, bharat financial,  bharat financial stocks, bharat financial shares, bharat financial TP price  News

Upgrade Marksans Pharma to ‘buy’ with TP of Rs 55

We upgrade Marksans Pharma (MPL) to Buy from Hold rating with a TP of Rs 55 (earlier Rs 45) based on 18x March’20E EPS of Rs 3.0. MPL’s Q3FY18 revenues and EBIDTA were lower than our expectations but net profit was in-lin

Marksans Pharma, EBIDTA, EBIDTA margin, USFDA, UK MHRA, EU businesses  News

Maintain ‘buy’ for Star Cement with TP of Rs 175

Star Cement delivered 4th consecutive quarter of robust profit, as its EBITDA/PAT shot up 60%/173% Y-o-Y. This is led by stability of robust pricing and Star’s sales recovery in NE region, lower sales outside NE region and

Star Cement, cement industry, Star Cement profit, Star Cement buy, Star Cement TP, robust pricing, Star cement sales recovery, EBITDA News

Maintain ‘outperformer’ on Can Fin Homes; TP Rs 487

Can Fin Homes (CFHL) loan growth was lower at 18.7% y-o-y compared to its past growth and compared to peers at Rs 15,058 crore.

Can Fin Homes market rating, cfhl market rating, market rating of cfhl News

ICICI Lombard: Profit growth at healthy pace

ICICI Lombard General Insurance (ICICI Lombard) was formed as a joint venture between ICICI Bank and Fairfax Financial Holdings.

ICICI Lombard, Profit, ICICI Bank, Fairfax Financial Holdings, insurance  News

Centrum puts Hold rating on Oriental Carbon and Chemicals with target price of Rs 1105

We retain our Hold rating on Oriental Carbon & Chemicals (OCCL) with a revised TP of Rs 1,105. Q2 performance was subdued and trailed our estimates due to lower than expected volumes as ramp-up at Mundra remained slow yet ste

Centrum, Centrum put hold, Centrum rated hold, Oriental Carbon & Chemicals, Mundra remained slow News

Retain buy on GIC Housing as asset quality risks limited: Centrum

We retain Buy on GIC Housing Finance (GICHF) with a target price of R340. Q4FY15 results were on the higher side...

Retain buy on GIC Housing as asset quality risks limited: Centrum
Switch to Hindi Edition